Anthonisen, N.R., Skeans, M.A., Wise, R.A., Manfreda, J., Kanner, R.E. and Connett, J.E. ( 2005) The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality: A Randomized Clinical Trial. Ann Intern Med142: 233-239.
2.
Boyle, P., Gray, N., Henningfield, J., Seffrin, J. and Zatonski, W. ( 2004) Tobacco and Public Health: Science and Policy. Oxford University Press: Oxford.
3.
Cacciola, R.R., Guarino, F. and Polosa, R. ( 2007) Relevance of Endothelial-Haemostatic Dysfunction in Cigarette Smoking. Curr Med Chem14: 1887-1892.
4.
Calverley, P.M., Anderson, J.A., Celli, B., Ferguson, G.T., Jenkins, C., Jones, P.W. et al. (2007) Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. N Engl J Med356: 775-789.
5.
Casella, G., Caponnetto, P. and Polosa, R. ( 2010) Therapeutic Advances in the Treatment of Nicotine Addiction: Present and Future. Ther Adv Chronic Dis (In Press).
6.
De Torres, J.P., Pinto-Plata, V., Casanova, C., Mullerova, H., Cordoba-Lanus, E., Muros De Fuentes, M. et al. (2008) C-Reactive Protein Levels and Survival in Patients with Moderate to Very Severe Copd. Chest133: 1336-1343.
7.
Dickstein, K., Cohen-Solal, A., Filippatos, G., Mcmurray, J.J., Ponikowski, P., Poole-Wilson, P.A. et al. (2008) Esc Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in Collaboration with the Heart Failure Association of the Esc (Hfa) and Endorsed by the European Society of Intensive Care Medicine (Esicm). Eur Heart J29: 2388-2442.
8.
Fiore, M.C., C.R.,.J., Baker, T.B., Bailey, W.C., Benowitz, N.L., Curry, S.J. et al. (2008) Treating Tobacco Use and Dependence: 2008 Update . Us Dept of Health and Human Services, Public Health and Human Service. May.
9.
Franciosi, L.G., Page, C.P., Celli, B.R., Cazzola, M., Walker, M.J., Danhof, M. et al. (2006) Markers of Disease Severity in Chronic Obstructive Pulmonary Disease. Pulm Pharmacol Ther19: 189-199.
10.
Gan, W.Q., Man, S.F., Senthilselvan, A. and Sin, D.D. ( 2004) Association between Chronic Obstructive Pulmonary Disease and Systemic Inflammation: A Systematic Review and a Meta-Analysis. Thorax59: 574-580.
11.
Hughes, J.R., Keely, J. and Naud, S. ( 2004) Shape of the Relapse Curve and Long-Term Abstinence among Untreated Smokers. Addiction99: 29-38.
12.
Komajda, M., Follath, F., Swedberg, K., Cleland, J., Aguilar, J.C., Cohen-Solal, A. et al. (2003) The Euroheart Failure Survey Programme-a Survey on the Quality of Care among Patients with Heart Failure in Europe. Part 2: Treatment. Eur Heart J24: 464-474.
13.
Kony, S., Zureik, M., Driss, F., Neukirch, C., Leynaert, B. and Neukirch, F. ( 2004) Association of Bronchial Hyperresponsiveness and Lung Function with C-Reactive Protein (Crp): A Population Based Study. Thorax59: 892-896.
14.
Lightwood, J.M. and Glantz, S.A. ( 1997) Short-Term Economic and Health Benefits of Smoking Cessation: Myocardial Infarction and Stroke. Circulation96: 1089-1096.
15.
Lowe, G.D. and Pepys, M.B. ( 2006) C-Reactive Protein and Cardiovascular Disease: Weighing the Evidence. Curr Atheroscler Rep8: 421-428.
16.
Lowe, G.D., Yarnell, J.W., Rumley, A., Bainton, D. and Sweetnam, P.M. ( 2001) C-Reactive Protein, Fibrin D-Dimer, and Incident Ischemic Heart Disease in the Speedwell Study: Are Inflammation and Fibrin Turnover Linked in Pathogenesis?Arterioscler Thromb Vasc Biol21: 603-610.
17.
Man, S.F., Connett, J.E., Anthonisen, N.R., Wise, R.A., Tashkin, D.P. and Sin, D.D. ( 2006) C-Reactive Protein and Mortality in Mild to Moderate Chronic Obstructive Pulmonary Disease. Thorax61: 849-853.
18.
Morjaria, J.B., Malerba, M. and Polosa, R.(2010) Biologic and Pharmacologic Therapies in Clinical Development for the Inflammatory Response in COPD. Drug Discov Today15(9-10): 396-405.
19.
Mortensen, E.M., Copeland, L.A., Pugh, M.J., Restrepo, M.I., De Molina, R.M., Nakashima, B. et al. (2009) Impact of Statins and Ace Inhibitors on Mortality after Copd Exacerbations. Respir Res10: 45.
20.
Pepys, M.B. and Hirschfield, G.M. ( 2003) C-Reactive Protein: A Critical Update. J Clin Invest111: 1805-1812.
21.
Ridker, P.M. ( 2001) High-Sensitivity C-Reactive Protein: Potential Adjunct for Global Risk Assessment in the Primary Prevention of Cardiovascular Disease . Circulation103: 1813-1818.
22.
Ridker, P.M. ( 2004) Inflammation in Atherothrombosis: How to Use High-Sensitivity C-Reactive Protein (Hscrp) in Clinical Practice. Am Heart Hosp J2: 4-9.
23.
Sinden, N.J. and Stockley, R.A. ( 2010) Chronic Obstructive Pulmonary Disease: An Update of Treatment Related to Frequently Associated Comorbidities. Ther Adv Chronic Dis: 43-57.
24.
Soyseth, V., Brekke, P.H., Smith, P. and Omland, T. ( 2007) Statin Use Is Associated with Reduced Mortality in Copd . Eur Respir J29: 279-283.
25.
Takabatake, N., Nakamura, H., Abe, S., Inoue, S., Hino, T., Saito, H. et al. (2000) The Relationship between Chronic Hypoxemia and Activation of the Tumor Necrosis Factor-Alpha System in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med161: 1179-1184.
26.
Tashkin, D.P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S. et al. (2008) A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. N Engl J Med359: 1543-1554.
27.
US Department of Health and Human Services ( 1990). The Health Benefits of Smoking Cessation (Dhhs Publication No. (Cdc) 90-8516). USA; US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
28.
Van Der Vaart, H., Postma, D.S., Timens, W. and Ten Hacken, N.H. ( 2004) Acute Effects of Cigarette Smoke on Inflammation and Oxidative Stress: A Review. Thorax59: 713-721.
29.
Wannamethee, S.G., Lowe, G.D., Shaper, A.G., Rumley, A., Lennon, L. and Whincup, P.H. ( 2005) Associations between Cigarette Smoking, Pipe/Cigar Smoking, and Smoking Cessation, and Haemostatic and Inflammatory Markers for Cardiovascular Disease. Eur Heart J26: 1765-1773.
30.
Willemse, B.W., Ten Hacken, N.H., Rutgers, B., Lesman-Leegte, I.G., Postma, D.S. and Timens, W. ( 2005) Effect of 1-Year Smoking Cessation on Airway Inflammation in Copd and Asymptomatic Smokers. Eur Respir J26: 835-845.
31.
Wilson, K., Gibson, N., Willan, A. and Cook, D. ( 2000) Effect of Smoking Cessation on Mortality after Myocardial Infarction: Meta-Analysis of Cohort Studies. Arch Intern Med160: 939-944.
32.
Yanbaeva, D.G., Dentener, M.A., Creutzberg, E.C., Wesseling, G. and Wouters, E.F. ( 2007) Systemic Effects of Smoking. Chest131: 1557-1566.
33.
Yusuf, S., Hawken, S., Ounpuu, S., Dans, T., Avezum, A., Lanas, F. et al. (2004) Effect of Potentially Modifiable Risk Factors Associated with Myocardial Infarction in 52 Countries (the Interheart Study): Case-Control Study. Lancet364: 937-952.